Lawmakers on the U.S. Senate Judiciary Committee urged the Trump administration to conduct a scientific review of a Justice Department-backed bill to classify all illicit chemical knockoffs of the potent painkiller fentanyl in the same legal category as heroin.
With an opioid molecule awaiting regulatory review, Nektar Therapeutics announced the launch of Inheris Biopharma, which will be responsible for the commercialization of NKTR-181.
Heron Therapeutics Receives Complete Response Letter For HTX-011 For The Management Of Postoperative Pain
Heron Therapeutics Inc. announced that the company received a Complete Response Letter from the U.S. Food and Drug Administration on April 30, 2019 regarding the New Drug Application for HTX-011 for the management of postoperative pain.
White Paper: Safety Profile of the Analgesic Trezix™ Capsules, Containing the Mild Opioid Dihydrocodeine
Privately held pharmaceutical company Wraser Pharmaceuticals announced the publication of a White Paper addressing opioid safety.
A non-opioid painkiller developed by Pfizer Inc. and Eli Lilly and Co. succeeded in reducing chronic low back pain when used in a stronger dose, results from a late-stage study showed.
Mumbai-based Glenmark Pharmaceuticals is spinning off its innovation business into a U.S.-based standalone company.
As the United States continues to grapple with the opioid epidemic, researchers have developed a new test that can measure pain biomarkers in the blood.
Pfizer and Eli Lilly announced that tanezumab hit two out of three co-primary endpoints in one dose and all three with a higher dose in patients with moderate-to-severe osteoarthritis pain in a Phase III trial.
Pfizer Inc. forecast 2019 profit and sales below Wall Street estimates as the company expects to take a blow from a stronger dollar and as well as the loss of patent on the blockbuster pain treatment Lyrica during 2019.
Pfizer is ending five preclinical programs in the biosimilar area and cutting 150 positions in Lake Forest, Illinois and in Chennai, India.